GlassScriptPhysician profile
Lucinda Smith
NPI 1487124616
$3,031.55
in general payments reported to CMS, 2019-2025
25 companies · $799 in 2025
The $799 reported for 2025 was more than what 82% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $618 · 2022: $181 · 2023: $395 · 2024: $1,038 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230 · Education: $2.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.21 |
| Education | $2.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $561.51 | 2021-2025 | Injectafer |
| Akebia Therapeutics INC | $339.31 | 2021-2025 | Vafseo |
| Amgen INC. | $313.43 | 2021-2024 | Krystexxa, Tavneos |
| Ani Pharmaceuticals, INC. | $296.42 | 2023-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $268.65 | 2021-2024 | Lokelma, Farxiga |
| Travere Therapeutics, INC. | $264.91 | 2024-2025 | Filspari |
| Calliditas Therapeutics US INC. | $232.53 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $100.41 | 2021-2023 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $91.63 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $91.27 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $91.25 | 2021-2025 | Terlivaz |
| Kyowa Kirin, INC. | $57.14 | 2024 | Crysvita |
| Aurinia Pharma U.S., INC. | $54.38 | 2024-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $37.92 | 2025 | Arexvy, Shingrix |
| Scpharmaceuticals INC. | $35.75 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $26.44 | 2025 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.44 | 2023 | Jardiance |
| Ardelyx, INC. | $22.16 | 2023 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $19.91 | 2024 | Givlaari |
| Vifor Pharma, INC. | $18.69 | 2024 | Veltassa |
| Medtronic, INC. | $18.45 | 2022 | |
| Lilly USA, LLC | $17.34 | 2025 | Jardiance |
| Genzyme Corporation | $17.06 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.37 | 2023 | Keveyis |
| Alexion Pharmaceuticals, INC. | $15.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucinda Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.